NCT07500467

Upadacitinib for Refractory Takayasu Arteritis

Analysis of the Efficacy and Safety of Upadacitinib in the Treatment of Refractory Takayasu Arteritis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 12 (actual)
• Sponsor: Liu Tian · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Takayasu arteritis (TKA) is an autoimmune vasculitis characterized with involvement of aorta and its primary branches.Upadacitinib is an oral, selective JAK1 inhibitor that potently inhibits JAK1 activity, representing a potential therapeutic option.This study aims to assess the efficacy and safety of upadacitinib in refractory Takayasu arteritis.

Detailed description

This is a single-arm trial conducted to evaluate the safety and efficacy of upadacitinib in refractory Takayasu arteritis (TKA). Patients in active TKA and unresponsive to at least 6 months of TNF-α inhibitors therapy were enrolled. Patients discontinued TNF-α inhibitors and received upadacitinib at 15 mg/day for up to 24 weeks, which was added to the glucocorticoid and immunosuppressants. The clinical manifestations, inflammatory indicators, imaging and treatment of patients were recorded by investigators during the follow up.

Conditions

• Takayasu Arteritis

Timeline

• Start date: 2024-03-19
• Primary completion: 2026-01-31
• Completion: 2026-02-01
• First posted: 2026-03-30
• Last updated: 2026-03-30

Locations

1 site across 1 country: China